AOD-9604 dosage protocol: correct oral-versus-injection trial claims, interpret hypothetical 5 mg aliquot calculations, and understand timing and safety gaps.
No validated human subcutaneous AOD-9604 dosage protocol is established by the reviewed evidence. A daily 1 mg injection should not be described as the usual human trial regimen: the larger obesity trial used oral administration, and the 2024 review did not identify human subcutaneous exposure.
AOD-9604 contains hGH residues 177-191 with an additional N-terminal tyrosine, making a modified 16-amino-acid peptide. The common name HGH fragment 176-191 should not be read as an unchanged native sequence. AOD-9604 has no FDA-approved human drug product, and a research label does not establish quality or authorize treatment.
What AOD-9604 Is and Why Dosing Is Uncertain
AOD-9604 was studied in humans as an anti-obesity candidate in the 2000s. Laboratory work suggested it could stimulate lipolysis and inhibit fat storage, and early human trials showed a trend toward fat loss.
The human program included substantial oral research, not only small studies. Its unsuccessful larger obesity trial did not establish an effective human subcutaneous regimen or an approved medicine.
Reported AOD-9604 Dosage Protocol Patterns
An aod 9604 dosage protocol should retain the actual route and formulation behind each study amount:
| Context | Amount or schedule | Route | Interpretation |
|---|---|---|---|
| Larger obesity trial | 0.25, 0.5, or 1 mg daily for 24 weeks | Oral | Historical study regimen; primary endpoint not met |
| Other human information reviewed in 2024 | Study-specific oral and intravenous information | Oral or intravenous | Not a subcutaneous dose-finding standard |
| Community injection schedule | Daily, split, or cycle claims vary | Subcutaneous | Not validated by the reviewed human evidence |
| Troche or nasal product | No cross-route conversion established | Formulation-specific | Cannot inherit oral trial amounts or results |
The 2024 human record concerned oral and intravenous administration. Saying the only human evidence is a daily subcutaneous injection reverses that record. Human pharmacokinetic or pharmacodynamic information for any route was not identified.
AOD-9604 Dosage Per Day for Weight Loss: What Trials Showed
The larger oral obesity trial summarized in FDA's 2024 AOD-9604 evaluation enrolled 536 people and randomized 502 to placebo or 0.25, 0.5, or 1 mg daily for 24 weeks. It did not show a significant advantage on the primary weight-loss endpoint at 12 weeks. Oral trial arms are not human injection recommendations. The sponsor terminated obesity development in 2007.
An earlier or secondary signal does not override an unsuccessful larger primary endpoint, establish a predictable amount of fat loss, or validate a different route. Any such result must retain its actual study conditions.
To be direct: AOD-9604 is not an FDA-approved weight loss drug, and no dose has been proven to produce meaningful, lasting fat loss in people. Any change in body weight should be judged alongside diet, activity, sleep, and routine clinical care.
Reconstitution, 5 mg Vial Math, and Storage
Aod-9604 reconstitution and dosage requires formulation-specific compatibility information. Bacteriostatic water and gentle mixing are not a universally validated recipe, and appearance alone cannot establish sterility or stability.
The 2024 evaluation explains that formulation, pH, concentration, temperature, impurities, and excipients can affect aggregation and degradation. It does not validate one diluent, acid recipe, or shelf life for every AOD-9604 product. There is no universal two-to-eight-degree storage rule or few-weeks shelf life for every mixed vial.
Working Out an AOD-9604 5 mg Dosage
For an aod 9604 5mg dosage calculation, the table assumes complete dissolution and the listed final solution volumes. The specified amounts are hypothetical laboratory aliquots, not human doses, solvent recommendations, or stable preparation recipes. U-100 units convert volume only.
| Assumed final volume for 5 mg | Calculated concentration | 1 mg aliquot | 500 mcg aliquot | 300 mcg aliquot |
|---|---|---|---|---|
| 1 mL | 5 mg/mL | 0.2 mL (20 units) | 0.1 mL (10 units) | 0.06 mL (6 units) |
| 2 mL | 2.5 mg/mL | 0.4 mL (40 units) | 0.2 mL (20 units) | 0.12 mL (12 units) |
| 3 mL | Approximately 1.67 mg/mL | 0.6 mL (60 units) | 0.3 mL (30 units) | 0.18 mL (18 units) |
| 5 mL | 1 mg/mL | 1 mL (100 units) | 0.5 mL (50 units) | 0.3 mL (30 units) |
Dilution changes the volume of a specified aliquot, assuming a compatible dissolved formulation. Measurement convenience cannot establish the solvent, solubility, stability, or a suitable human injection volume.
Dosing for Men vs. Women and Route Options
The reviewed evidence does not establish a sex-specific aod 9604 dosage for men or women. It is inaccurate to say all participants received the same daily human injection; the larger oral trial had several randomized treatment groups.
Body weight and clinical history do not supply a validated AOD-9604 dose formula without direct evidence. A clinician can assess medical questions but cannot turn an unsupported dosing rule into a proven regimen.
Injection vs. Oral vs. Sublingual
| Route | 2024 review finding | Interpretation |
|---|---|---|
| Subcutaneous | Human exposure not identified | No validated human regimen follows |
| Oral | Substantial clinical development, including the larger obesity trial | Trial amounts do not transfer to retail capsules or other routes |
| Intravenous | Human study information available | Cannot establish subcutaneous or oral dose equivalence |
| Sublingual or nasal | No validated cross-route conversion established by this review | Retail availability does not establish exposure or benefit |
Human oral and intravenous research exists. The reviewed evidence does not validate subcutaneous, nasal, or troche regimens or establish that those routes are equivalent.
Safety, Legal Status, and Key Takeaways
- AOD-9604 has no FDA-approved human drug product.
- The 2026 WADA Prohibited List names AOD-9604 under S2.2.3, prohibited at all times.
- The oral and intravenous safety record cannot establish a generally mild injection profile.
- The larger oral trial ran for 24 weeks, but that does not establish long-term human subcutaneous safety.
Peptides purchased outside a licensed pharmacy are not guaranteed to be sterile, pure, or correctly labeled. Anyone considering AOD-9604 should discuss it with a healthcare professional and weigh unproven benefits against unknown long-term risks.
The larger oral trial did not meet its primary weight-loss endpoint, and its historical regimen cannot validate a daily human injection. No FDA-approved AOD-9604 human product exists. Correct concentration arithmetic remains distinct from clinical dose selection.
Frequently Asked Questions
What is the typical AOD-9604 dosage per day?
No validated human subcutaneous daily amount is established by the reviewed evidence. The larger oral trial used 0.25, 0.5, or 1 mg daily for 24 weeks; it did not validate a daily 1 mg injection or a smaller community schedule.
How do you reconstitute a 5 mg vial of AOD-9604?
No universal solvent or volume is established. As hypothetical laboratory arithmetic, 5 mg in a final volume of 2 mL gives 2.5 mg/mL, and a specified 1 mg aliquot occupies 0.4 mL or 40 U-100 units. This does not validate a preparation recipe or a human dose.
Is AOD-9604 legal or FDA-approved?
No FDA-approved AOD-9604 human drug product exists. A research label does not authorize treatment or settle every applicable legal question. The 2026 WADA list names AOD-9604 under S2.2.3, prohibited at all times for athletes subject to those rules.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.